Pay in 4 interest-free payments of $5.16 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
For use in manufacturing of cellular or gene therapy products
Snapshot: The TRIUMPH-OUTCOMES study TRIUMPH-OUTCOMES (J1I-MC-GZBO) is a phase 3, randomised, double-blind, placebo-controlled, event-driven study to investigate the effect of Retatrutide on the incidence of major adverse cardiovascular events and the decline in kidney function in participants with BMI 27 and atherosclerotic cardiovascular disease and/or chronic kidney disease
So, store your medication in its labeled, original packaging to protect it from damage something thats a good idea no matter your method of transportation and comply with regulations
Phase 1 Trials In a first-in-human, randomized, placebo-controlled, single ascending dose, phase 1 trial in healthy participants, retatrutide demonstrated a favourable safety profile (similar to other incretin-based therapies) and early signs of efficacy with dose-dependent WL [42]
US$ 20.33
US$ 28.43
US$ 21.22
US$ 23.67
